An Open-Label, Multi-center Protocol to Observe the Effects of Pegylated Interferon Alfa-2a (PEGASYS (R)) as Monotherapy in Patients with Chronic Hepatitis B who have Participated in Previous Roche or Roche Partner Protocols.
Phase of Trial: Phase I
Latest Information Update: 03 Mar 2014
At a glance
- Drugs Peginterferon alfa-2a (Primary)
- Indications Hepatitis B
- Focus Therapeutic Use
- Sponsors Roche
- 03 Mar 2014 Status changed from active, no longer recruiting to completed according to ClinicalTrials.gov record.
- 06 Jul 2012 Actual patient number changed from 21 to 29 according to ClinicalTrials.gov.
- 21 May 2012 Actual patient number is 24 as reported by ClinicalTrials.gov.